Prion Protein Is Decreased in Alzheimer's Brain and Inversely Correlates with BACE1 Activity, Amyloid-β Levels and Braak Stage

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Whitehouse, Isobel J ^a   Miners, J Scott ^b   Glennon, Elizabeth B C ^a   Kehoe, Patrick G ^b   Love, Seth ^b   Kellett, Katherine A B ^a   Hooper, Nigel M ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; BETA SECRETASE 1; CELLULAR PRION PROTEIN; CONTACTIN; CONTACTIN 5; PRION PROTEIN; UNCLASSIFIED DRUG;

AGED; ALZHEIMER DISEASE; ARTICLE; BRAAK STAGE; BRAIN LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE CLASSIFICATION; DOWN SYNDROME; ENZYME ACTIVITY; FRONTAL CORTEX; HUMAN; HUMAN TISSUE; PROTEIN EXPRESSION;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID PRECURSOR PROTEIN SECRETASES; ASPARTIC ACID ENDOPEPTIDASES; BRAIN; CASE-CONTROL STUDIES; CONTACTINS; DOWN SYNDROME; FEMALE; FRONTAL LOBE; HUMANS; MALE; MIDDLE AGED; PRIONS;

EID: 84875925685     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0059554     Document Type: Article

References (41)

1. Burns A, Iliffe S, (2009) Alzheimer's disease. BMJ 338: b158.
2. Mount C, Downton C, (2006) Alzheimer disease: progress or profit? Nat Med 12: 780-784.
3. Iqbal K, Alonso Adel C, Chen S, Chohan MO, El-Akkad E, et al. (2005) Tau pathology in Alzheimer disease and other tauopathies. Biochim Biophys Acta 1739: 198-210.
4. Braak H, Braak E, (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82: 239-259.
5. Cras P, Smith MA, Richey PL, Siedlak SL, Mulvihill P, et al. (1995) Extracellular neurofibrillary tangles reflect neuronal loss and provide further evidence of extensive protein cross-linking in Alzheimer disease. Acta Neuropathol 89: 291-295.
6. Bai Y, Markham K, Chen F, Weerasekera R, Watts J, et al. (2008) The in vivo brain interactome of the amyloid precursor protein. Mol Cell Proteom 7: 15-34.
7. Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, et al. (2009) Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet 41: 1088-1093.
8. Biffi A, Anderson CD, Desikan RS, Sabuncu M, Cortellini L, et al. (2010) Genetic variation and neuroimaging measures in Alzheimer disease. Arch Neurol 67: 677-685.
9. Cole SL, Vassar R, (2008) The role of amyloid precursor protein processing by BACE1, the beta-secretase, in Alzheimer disease pathophysiology. J Biol Chem 283: 29621-29625.
10. Fukumoto H, Cheung BS, Hyman BT, Irizarry MC, (2002) Beta-secretase protein and activity are increased in the neocortex in Alzheimer disease. Arch Neurol 59: 1381-1389.
11. Li R, Lindholm K, Yang LB, Yue X, Citron M, et al. (2004) Amyloid beta peptide load is correlated with increased beta-secretase activity in sporadic Alzheimer's disease patients. Proc Natl Acad Sci USA 101: 3632-3637.
12. Miners JS, van Helmond Z, Kehoe PG, Love S, (2010) Changes with age in the activities of beta-secretase and the Abeta-degrading enzymes neprilysin, insulin-degrading enzyme and angiotensin-converting enzyme. Brain Pathol 20: 794-802.
13. He W, Lu Y, Qahwash I, Hu XY, Chang A, et al. (2004) Reticulon family members modulate BACE1 activity and amyloid-beta peptide generation. Nat Med 10: 959-965.
14. Majercak J, Ray WJ, Espeseth A, Simon A, Shi XP, et al. (2006) LRRTM3 promotes processing of amyloid-precursor protein by BACE1 and is a positional candidate gene for late-onset Alzheimer's disease. Proc Natl Acad Sci USA 103: 17967-17972.
15. Parkin ET, Watt NT, Hussain I, Eckman EA, Eckman CB, et al. (2007) Cellular prion protein regulates beta-secretase cleavage of the Alzheimer's amyloid precursor protein. Proc Natl Acad Sci USA 104: 11062-11067.
16. Hooper NM, Turner AJ, (2008) A new take on prions: preventing Alzheimer's disease. Trends Biochem Sci 33: 151-155.
17. Whitehouse IJ, Jackson C, Turner AJ, Hooper NM, (2010) Prion protein is reduced in aging and in sporadic but not in familial Alzheimer's disease. J Alzheimer's Dis: JAD 22: 1023-1031.
18. Fukumoto H, Rosene DL, Moss MB, Raju S, Hyman BT, et al. (2004) Beta-secretase activity increases with aging in human, monkey, and mouse brain. Am J Pathol 164: 719-725.
19. Griffiths HH, Whitehouse IJ, Baybutt H, Brown D, Kellett KA, et al. (2011) Prion protein interacts with BACE1 protein and differentially regulates its activity toward wild type and Swedish mutant amyloid precursor protein. J Biol Chem 286: 33489-33500.
20. Menendez M, (2005) Down syndrome, Alzheimer's disease and seizures. Brain Dev 27: 246-252.
21. Stimson E, Hope J, Chong A, Burlingame AL, (1999) Site-specific characterization of the N-linked glycans of murine prion protein by high-performance liquid chromatography/electrospray mass spectrometry and exoglycosidase digestions. Biochem 38: 4885-4895.
22. Miners JS, Morris S, Love S, Kehoe PG, (2011) Accumulation of insoluble amyloid-beta in down's syndrome is associated with increased BACE-1 and neprilysin activities. J Alzheimer's Dis 23: 101-108.
23. Matthews FE, McKeith I, Bond J, Brayne C, (2007) Reaching the population with dementia drugs: what are the challenges? Int J Ger Psych 22: 627-631.
24. Brayne C, (2007) The elephant in the room - healthy brains in later life, epidemiology and public health. Nat Rev Neurosci 8: 233-239.
25. Vincent B, Sunyach C, Orzechowski HD, St George-Hyslop P, Checler F, (2009) p53-Dependent transcriptional control of cellular prion by presenilins. J Neurosci 29: 6752-6760.
26. Lewis V, Whitehouse IJ, Baybutt H, Manson JC, Collins SJ, et al. (2012) Cellular prion protein expression is not regulated by the Alzheimer's amyloid precursor protein intracellular domain. PloS one 7: e31754.
27. Saijo E, Scheff SW, Telling GC, (2011) Unaltered prion protein expression in Alzheimer disease patients. Prion 5: 109-116.
28. Beyer N, Coulson DT, Heggarty S, Ravid R, Hellemans J, et al. (2012) Zinc Transporter mRNA Levels in Alzheimer's Disease Postmortem Brain. J Alzheimer's Dis 29: 863-873.
29. Peles E, Nativ M, Lustig M, Grumet M, Schilling J, et al. (1997) Identification of a novel contactin-associated transmembrane receptor with multiple domains implicated in protein-protein interactions. EMBO J 16: 978-988.
30. Rios JC, Melendez-Vasquez CV, Einheber S, Lustig M, Grumet M, et al. (2000) Contactin-associated protein (Caspr) and contactin form a complex that is targeted to the paranodal junctions during myelination. J Neurosci 20: 8354-8364.
31. Gollan L, Salomon D, Salzer JL, Peles E, (2003) Caspr regulates the processing of contactin and inhibits its binding to neurofascin. J Cell Biol 163: 1213-1218.
32. Watt NT, Taylor DR, Kerrigan TL, Griffiths HH, Rushworth JV, et al. (2012) Prion protein facilitates uptake of zinc into neuronal cells. Nat Ccomm 3: 1134.
33. Bush AI, Pettingell WH, Multhaup G, d Paradis M, Vonsattel JP, et al. (1994) Rapid induction of Alzheimer A beta amyloid formation by zinc. Science 265: 1464-1467.
34. Lee JY, Cole TB, Palmiter RD, Suh SW, Koh JY, (2002) Contribution by synaptic zinc to the gender-disparate plaque formation in human Swedish mutant APP transgenic mice. Proc Natl Acad Sci USA 99: 7705-7710.
35. Deshpande A, Kawai H, Metherate R, Glabe CG, Busciglio J, (2009) A Role for Synaptic Zinc in Activity-Dependent A{beta} Oligomer Formation and Accumulation at Excitatory Synapses. J Neurosci 29: 4004-4015.
36. Morris JC, Heyman A, Mohs RC, Hughes JP, van Belle G, et al. (1989) The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer's disease. Neurology 39: 1159-1165.
37. van Helmond Z, Miners JS, Kehoe PG, Love S, (2010) Higher soluble amyloid beta concentration in frontal cortex of young adults than in normal elderly or Alzheimer's disease. Brain Pathol 20: 787-793.
38. van Helmond Z, Miners JS, Kehoe PG, Love S, (2010) Oligomeric Abeta in Alzheimer's disease: relationship to plaque and tangle pathology, APOE genotype and cerebral amyloid angiopathy. Brain Pathol 20: 468-480.
39. Chalmers K, Wilcock GK, Love S, (2003) APOE epsilon 4 influences the pathological phenotype of Alzheimer's disease by favouring cerebrovascular over parenchymal accumulation of A beta protein. Neuropathol Appl Neurobiol 29: 231-238.
40. Ballard CG, Chalmers KA, Todd C, McKeith IG, O'Brien JT, et al. (2007) Cholinesterase inhibitors reduce cortical Abeta in dementia with Lewy bodies. Neurology 68: 1726-1729.
41. Miners JS, Baig S, Tayler H, Kehoe PG, Love S, (2009) Neprilysin and insulin-degrading enzyme levels are increased in Alzheimer disease in relation to disease severity. J Neuropathol Expt Neurol 68: 902-914.